Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Patients with Cystic Fibrosis and a G551D or Homozygous F508del Mutation: Similar Lung Function Decline.

Sawicki GS, McKone EF, Millar SJ, Pasta DJ, Konstan MW, Lubarsky B, Wagener JS.

Am J Respir Crit Care Med. 2017 Jun 15;195(12):1673-1676. doi: 10.1164/rccm.201608-1678LE. No abstract available.

PMID:
28617084
2.

Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.

Konstan MW, McKone EF, Moss RB, Marigowda G, Tian S, Waltz D, Huang X, Lubarsky B, Rubin J, Millar SJ, Pasta DJ, Mayer-Hamblett N, Goss CH, Morgan W, Sawicki GS.

Lancet Respir Med. 2017 Feb;5(2):107-118. doi: 10.1016/S2213-2600(16)30427-1. Epub 2016 Dec 21.

PMID:
28011037
3.

Nutritional Status Improved in Cystic Fibrosis Patients with the G551D Mutation After Treatment with Ivacaftor.

Borowitz D, Lubarsky B, Wilschanski M, Munck A, Gelfond D, Bodewes F, Schwarzenberg SJ.

Dig Dis Sci. 2016 Jan;61(1):198-207. doi: 10.1007/s10620-015-3834-2. Epub 2015 Aug 7.

PMID:
26250833
4.

Requirement for chitin biosynthesis in epithelial tube morphogenesis.

Devine WP, Lubarsky B, Shaw K, Luschnig S, Messina L, Krasnow MA.

Proc Natl Acad Sci U S A. 2005 Nov 22;102(47):17014-9. Epub 2005 Nov 15.

5.

Tube morphogenesis: making and shaping biological tubes.

Lubarsky B, Krasnow MA.

Cell. 2003 Jan 10;112(1):19-28. Review.

6.

Supplemental Content

Loading ...
Support Center